Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of VALIANTLAB
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 89.92 | 51.41 | 59.55 | 40.52 | 30.59 | 18.88 | 21.48 | 35.23 | 57.79 | 46.82 | 46.20 | 52.46 | 91.98 |
| Expenses + | 81.30 | 47.59 | 60.94 | 46.83 | 35.12 | 21.27 | 28.22 | 34.61 | 53.97 | 44.43 | 46.12 | 53.35 | 87.17 |
| Operating Profit | 8.62 | 3.82 | -1.39 | -6.31 | -4.53 | -2.39 | -6.74 | 0.62 | 3.82 | 2.39 | 0.08 | -0.89 | 4.81 |
| OPM % | 9.59% | 7.43% | -2.33% | -15.57% | -14.81% | -12.66% | -31.38% | 1.76% | 6.61% | 5.10% | 0.17% | -1.70% | 5.23% |
| Other Income + | 1.72 | 2.44 | 2.96 | 1.78 | 2.50 | 2.81 | 3.36 | 1.58 | -2.31 | 0.66 | 0.87 | 0.63 | 0.17 |
| Interest | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.01 | 0.06 | 0.05 | 0.07 | 0.14 | 0.68 | 1.01 |
| Depreciation | 0.44 | 0.46 | 0.49 | 0.49 | 0.52 | 0.53 | 0.52 | 0.52 | 0.52 | 0.53 | 0.53 | 2.05 | 2.93 |
| Profit before tax | 9.87 | 5.78 | 1.06 | -5.04 | -2.57 | -0.16 | -3.91 | 1.62 | 0.94 | 2.45 | 0.28 | -2.99 | 1.04 |
| Tax % | 20.67% | 26.12% | 25.47% | -30.75% | -51.75% | 218.75% | 21.23% | -44.44% | 25.53% | 25.71% | 25.00% | 136.12% | -68.27% |
| Net Profit + | 7.83 | 4.27 | 0.79 | -3.50 | -1.24 | -0.51 | -4.74 | 2.35 | 0.70 | 1.82 | 0.20 | -7.06 | 1.76 |
| EPS in Rs | 1.92 | 1.05 | 0.19 | -0.64 | -0.23 | -0.09 | -0.87 | 0.43 | 0.13 | 0.34 | 0.04 | -1.30 | 0.32 |
Financials of VALIANTLAB
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 334 | 182 | 133 | 237 |
| Expenses + | 299 | 190 | 138 | 231 |
| Operating Profit | 35 | -8 | -5 | 6 |
| OPM % | 11% | -5% | -4% | 3% |
| Other Income + | 5 | 10 | 5 | 2 |
| Interest | 0 | 0 | 0 | 2 |
| Depreciation | 2 | 2 | 2 | 6 |
| Profit before tax | 38 | -1 | -2 | 1 |
| Tax % | 24% | -142% | 46% | 525% |
| Net Profit + | 29 | 0 | -2 | -3 |
| EPS in Rs | 7.13 | 0.06 | -0.41 | -0.60 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of VALIANTLAB
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 33 | 43 | 43 | 54 |
| Reserves | 68 | 193 | 191 | 257 |
| Borrowings + | 60 | 77 | 122 | 46 |
| Other Liabilities + | 52 | 29 | 45 | 107 |
| Total Liabilities | 213 | 343 | 401 | 464 |
| Fixed Assets + | 48 | 50 | 48 | 227 |
| CWIP | 1 | 43 | 156 | 6 |
| Investments | 34 | 38 | 0 | 28 |
| Other Assets + | 130 | 212 | 197 | 202 |
| Total Assets | 213 | 343 | 401 | 464 |
Financials of VALIANTLAB
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 56 | 2 | 1 | -10 |
| Cash from Investing Activity + | -55 | -144 | -53 | 7 |
| Cash from Financing Activity + | -1 | 152 | 45 | 2 |
| Net Cash Flow | -0 | 10 | -7 | -1 |
| Free Cash Flow | 18 | -44 | -112 | -45 |
| CFO/OP | 185% | -11% | 25% | -147% |
Financials of VALIANTLAB
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 97 | 92 | 197 | 144 |
| Inventory Days | 17 | 22 | 13 | 84 |
| Days Payable | 62 | 56 | 128 | 174 |
| Cash Conversion Cycle | 52 | 57 | 82 | 54 |
| Working Capital Days | 70 | 106 | 156 | 156 |
| ROCE % | -2% | -1% | 1% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…